Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Suven Life Sciences Plunges 5%; BSE HEALTHCARE Index Down 0.1%
Wed, 10 Jul 10:14

Suven Life Sciences Plunges 5%; BSE HEALTHCARE Index Down 0.1%Image source: KanawatTH/www.istockphoto.com

Suven Life Sciences share price has plunged 5% and is presently trading at Rs 134.2.

Meanwhile, the BSE HEALTHCARE index is at 38,414.2 (down 0.1%).

Among the top losers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (down 2.0%) and ALKEM LABORATORIES (down 1.5%).

Pfizer (up 3.4%) and FORTIS HEALTHCARE (up 2.4%) are among the top gainers today.

Over the last one year, Suven Life Sciences has moved up from Rs 62.1 to Rs 134.2, registering a gain of Rs 72.1 (up 116.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 25,922.2 to 38,414.2, registering a gain of 48.2% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 103.3%), Lupin (up 101.7%) and Cadila Healthcare (up 98.8%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,058.7 (down 0.4%).

The top losers among the BSE Sensex today are M&M (down 5.7%) and SBI (down 1.4%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.

In the meantime, NSE Nifty is at 24,333.2 (down 0.4%). M&M and Shriram Transport are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,344.2 to 80,058.7, registering a gain of 14,714.5 points (up 22.5%).

Suven Life Sciences Financial Update...

Suven Life Sciences net profit grew 4.0% YoY to Rs -265 million for the quarter ended March 2024, compared to a loss of Rs 276 million a year ago. Net sales declined 8.7% to Rs 24 million during the period as against Rs 26 million in January-March 2023.

For the year ended March 2024, Suven Life Sciences reported 11.2% increase in net profit to Rs -1,051 million compared to net loss of Rs 1,183 million during FY23. Revenue of the company fell 13.6% to Rs 117 million during FY24.

The current Price to earnings ratio of Suven Life Sciences, based on rolling 12 month earnings, stands at -27.8.


Equitymaster requests your view! Post a comment on "Suven Life Sciences Plunges 5%; BSE HEALTHCARE Index Down 0.1%". Click here!